Zobrazeno 1 - 10
of 18
pro vyhledávání: '"EYCK VON DER HEYDE"'
Autor:
Frank Griesinger, MD, PhD, Wilfried E.E. Eberhardt, MD, PhD, Wolfgang M. Brueckl, MD, PhD, Horst-Dieter Hummel, MD, PhD, Bastian Jaeschke, MD, Jens Kern, MD, Claas Wesseler, MD, Martina Jänicke, PdD, Annette Fleitz, PhD, Stefan Zacharias, PhD, Annette Hipper, PhD, Annika Groth, MD, PhD, Wilko Weichert, MD, PhD, Steffen Dörfel, Volker Petersen, MD, Jan Schröder, MD, Jochen Wilke, MD, Martin Sebastian, MD, Michael Thomas, MD, PhD, Juliana Ababei, Jürgen Alt, Andreas Ammon, Jürgen Anhuf, Ivo Azeh, Stefan Bauer, Dirk Behringer, Winfried Berger, Christiane Bernhardt, Mathias Bertram, Michael Boesche, Sabine Bohnet, Harald-Robert Bruch, Wolfgang Brückl, Ulrike Burkhard-Meier, Petros Christopoulos, Klaus-Ulrich Däßler, Maike de Wit, Tobias Dechow, Reinhard Depenbusch, Lutz Dietze, Markus Dommach, Wilfried Eberhardt, Corinna Elender, Wolfgang Elsel, Till-Oliver Emde, Martin Faehling, Thomas Fietz, Jürgen R. Fischer, Dimitri Flieger, Anke Freidt, Werner Freier, Christian Frenzel, Florian Fuchs, Roswitha Fuchs, Tobias Gaska, Wolfgang Gleiber, Christian Grah, Frank Griesinger, Christian Grohé, Matthias Groschek, Björn Güldenzoph, Andreas Günther, Siegfried Haas, Matthias Hackenthal, Volker Hagen, Lars Hahn, Verena Hannig Carla, Richard Hansen, Hanns-Detlev Harich, Monika Heilmann, Kathrin Heinrich, Christiane Hering-Schubert, Jörg Heßling, Petra Hoffknecht, Patricia Hortig, Gerdt Hübner, Horst-Dieter Hummel, Ulrich Hutzschenreuter, Thomas Illmer, Georg Innig, Bastian Jaeschke, Christian Junghanß, Ulrich Kaiser, Haytham Kamal, Kato Kambartel, Jens Kern, Martin Kimmich, Dorothea Kingreen, Heinz Kirchen, Martine Klausmann, Ortwin Klein, Konrad Kokowski, Wolfgang Körber, Cornelius Kortsik, Dirk Koschel, Benoit Krämer, Beate Krammer-Steiner, Eckart Laack, Christof Lamberti, Rumo David Leistner, Christoph Losem, Andreas Lück, Christoph Maintz, Kerstin Martin, Dirk Medgenberg, Martin Metzenmacher, Christian Meyer zum Büschenfelde, Philipp Meyn, Enno Moorahrend, Annette Müller, Lothar Müller, Michael Neise, Holger Nückel, Arnd Nusch, Tobias Overbeck, Henning Pelz, Volker Petersen, Bettina Peuser, Margarete Plath, Winfried J. Randerath, Jacqueline Rauh, Martin Reck, Dietmar Reichert, Niels Reinmuth, Marcel Reiser, Roland Repp, Daniel Reschke, Achim Rittmeyer, Yolanda Rodemer, Sandra Sackmann, Parvis Sadjadian, Reiner Sandner, Annette Sauer, Harald Schäfer, Christoph Schaudt, Rudolf Schlag, Burkhard Schmidt, Stephan Schmitz, Jan Schröder, Michael Schroeder, Mathias Schulze, Christian Schumann, Wolfgang Schütte, Martin Schwaiblmair, Florian Schwindt Peter, Martin Sebastian, Bernd Seese, Gernot Seipelt, Thomas Sorgenfrei, Johannes Steiff, Heike Steiniger, Tanja Trarbach, Amanda Tufman, Jens Uhlig, Ursula Vehling-Kaiser, Eyck von der Heyde, Ulla von Verschuer, Cornelius Waller, Thomas Wehler, Georg Weißenborn, Florian Weißinger, Martin Wermke, Claas Wesseler, Jörg Wiegand, Stefan Wilhelm, Jochen Wilke, Mark-Oliver Zahn, Matthias Zaiss, Matthias Zeth
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100626- (2024)
Introduction: Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNS
Externí odkaz:
https://doaj.org/article/193c505adea04fdda590997c6e7e69c0
Autor:
Georg-Nikolaus Franke, Gunnar Loewe, Marcel Reiser, Hartmut Linde, Andreas Josting, Eyck von der Heyde, Rudolf Weide, Hans Tesch, Arndt Nusch, Jolanta Dengler, Kathleen Jentsch-Ullrich
Publikováno v:
HemaSphere, Vol 7, p e4962270 (2023)
Externí odkaz:
https://doaj.org/article/e75f25079aee4426a4e5fc7952668e0c
Autor:
Felicitas Schulz, Ulrich Hauch, Sandra Ketzler-Henkel, Eyck von der Heyde, Michael Koenigsmann, Michael Lauseker, Nora Schulte, Ulrich Germing
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 20, p 6569 (2023)
Myelodysplastic syndromes and myeloproliferative neoplasms both represent hematologic diseases associated with bone marrow failure often resulting in anemia. For those patients, transfusion of red blood cell (RBC) units is essential but results in ir
Externí odkaz:
https://doaj.org/article/73a08c1175134727b46f5480eb87a423
Autor:
Martin Sebastian, Andreas Gröschel, Sylvia Gütz, Holger Schulz, Harald Müller-Huesmann, Rüdiger Liersch, Eyck von der Heyde, Jörg Wiegand, Dieter Ukena, Joachim Bargon, Wolfgang Schütte, Jorge Riera-Knorrenschild, Jürgen R. Fischer, Frank Griesinger, Victoria Allan, Daniela Waldenberger, Christian Schumann
Publikováno v:
Journal of Immunotherapy. 45:89-99
Nivolumab was the first immune checkpoint inhibitor approved for use in advanced non-small cell lung cancer (NSCLC). This noninterventional, prospective cohort study investigates real-world effectiveness of nivolumab in pretreated NSCLC patients in G
Autor:
Oliver Meyer, Rudolf Schlag, Thomas Stauch, Bastian Fleischmann, Marcel Reiser, Dietrich Kaempfe, Timo Behlendorf, Manfred Welslau, Eyck von der Heyde, Steffen Dörfel, Claudia Willy, Martina Stauch
Publikováno v:
Blood. 140:2683-2684
Autor:
Norbert, Marschner, Susanna, Hegewisch-Becker, Marcel, Reiser, Eyck, von der Heyde, Mathias, Bertram, Stephan H, Hollerbach, Stephan, Kreher, Thomas, Wolf, Adrian, Binninger, Marco, Chiabudini, Anja, Kaiser-Osterhues, Martina, Jänicke
Publikováno v:
International journal of cancerREFERENCES. 152(3)
There is no prospective, randomised head-to-head trial comparing first-line FOLFIRINOX and gemcitabine/nab-paclitaxel in advanced pancreatic cancer. We assess real-world effectiveness and quality of life (QoL) of both regimens using a new prognostic
Autor:
Armin, Gerger, Wolfgang, Eisterer, Stefan, Fuxius, Sara, Bastian, Dieter, Koeberle, Manfred, Welslau, Dilara Akhoundova, Sanoyan, Christian, Maas, Jens, Uhlig, Klaus, Fenchel, Richard, Greil, Eyck, VON DER Heyde, Gaëlle Rhyner, Agocs, Rudolf, Weide, Monika, Schwager, Frank, Reichenbach, Dominik Paul, Modest, Ralph, Fritsch
Publikováno v:
Anticancer research. 42(10)
Metastatic colorectal cancer (mCRC) is a heterogeneous disease with distinct molecular subtypes. The BRAFAnonymized data from BRAFForty-two patients were eligible for analysis (mean age 62.1 years, 47.6% female). At initial diagnosis, 20 patients (47
Autor:
Sebastian Stintzing, Eyck von der Heyde, Jan Wierecky, Dieter Bürkle, Helmut Forstbauer, Gerdt Hübner, Burkhard Schmidt, Jan Schroeder, Andrea Distelrath, Marion Flum, Frank Reichenbach, Dirk Arnold, Ralph M Fritsch, Armin Gerger, Susanna Hegewisch-Becker, Arndt Vogel, Anna Dorothea Wagner, Thomas Winder, Dieter Koeberle, Gerald W. Prager
Publikováno v:
Journal of Clinical Oncology. 41:34-34
34 Background: BRAF V600E-mutant metastatic colorectal cancer (mCRC) is associated with a poor prognosis and limited clinical data. Based on results from the BEACON CRC trial, targeted treatment with encorafenib plus cetuximab (E+C) is available as a
Autor:
ARMIN GERGER, WOLFGANG EISTERER, STEFAN FUXIUS, SARA BASTIAN, DIETER KOEBERLE, MANFRED WELSLAU, DILARA AKHOUNDOVA SANOYAN, CHRISTIAN MAAS, JENS UHLIG, KLAUS FENCHEL, RICHARD GREIL, EYCK VON DER HEYDE, GAËLLE RHYNER AGOCS, RUDOLF WEIDE, MONIKA SCHWAGER, FRANK REICHENBACH, DOMINIK PAUL MODEST, RALPH FRITSCH
Publikováno v:
Gerger, Armin; Eisterer, Wolfgang; Fuxius, Stefan; Bastian, Sara; Koeberle, Dieter; Welslau, Manfred; Akhoundova Sanoyan, Dilara; Maas, Christian; Uhlig, Jens; Fenchel, Klaus; Greil, Richard; von der Heyde, Eyck; Rhyner Agocs, Gaëlle; Weide, Rudolf; Schwager, Monika; Reichenbach, Frank; Modest, Dominik Paul; Fritsch, Ralph (2022). Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma-MORSECRC. Anticancer research, 42(10), pp. 4773-4785. International Inst. of Anticancer Research 10.21873/anticanres.15982
BACKGROUND/AIM Metastatic colorectal cancer (mCRC) is a heterogeneous disease with distinct molecular subtypes. The BRAFV600E-mutation found in approximately 8-12% of mCRC patients is associated with poor prognosis. Guideline recommendations for this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2790dec295899d86fd9bcfece5d03e6f
Autor:
Marc-Oliver Grimm, Viktor Grünwald, Harald Müller-Huesmann, Philipp Ivanyi, Martin Schostak, Eyck von der Heyde, Wolfgang Schultze-Seemann, Hanjo Belz, Martin Bögemann, Meng Wang, Martin Herber, Jens Bedke
Publikováno v:
European urology focus. 8(5)
Background: Nivolumab monotherapy is approved for the treatment of advanced renal cell carcinoma (aRCC) after prior therapy on the basis of results from CheckMate 025. Objective: The NORA (NivOlumab in Renal cell cArcinoma) noninterventional study (N